Patent · US Expired

Compounds enhancing antitumor activity of other cytotoxic agents

US6130217A · kind A · utility

116Cited by
3References
4Claims
0Family size

Assignee

Inventors

Key dates

Filing dateSep 20, 1995
Grant dateOct 10, 2000
Priority date
Expiry dateSep 20, 2015

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY02A50/30
  • WIPO fieldOrganic fine chemistry
  • WIPO sectorChemistry

Abstract

This invention relates to certain heterocyclic compounds and their pharmaceutically acceptable salts, which are useful for sensitizing multidrug-resistant tumor cells to anticancer agents and multidrug resistant forms of malaria, tuberculosis, leishmania and amoebic dysentery to chemotherapeutants. The compounds and their pharmaceutically acceptable salts are also inhibitors of the active drug transport capability of P-glycoprotein which is encoded by the human MDR1 gene, as well as of certain other related ATP-binding-cassette transporters from eukaryotic and prokaryotic organisms (e.g., pfmdr from Plasmodium falciprum, and murine mdr1 and mdr3 gene products).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.